FDA advisers to review research peptide access in July meeting

Advisers to the Food and Drug Administration will meet on 23-24 July to consider whether to ease restrictions on seven research peptides sold online as wellness aids. The committee will review BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax and Epitalon. The panel has three voting members, six vacancies and one non-voting pharmaceutical industry representative.

Background on the 2023 restrictions A 2023 decision by the Biden administration barred compounding pharmacies from producing 19 research peptides after the FDA cited risks including priapism and potential tumor growth. The substances are short-chain amino acids marketed for uses such as injury recovery and age-related conditions, though evidence of safety and efficacy in humans ranges from limited to nonexistent.

Industry and medical views A retail pharmacist in Michigan said many patients are waiting for the peptides to receive Category 1 legal status. The chief medical officer of Hims stated that preclinical evidence exists for some peptides and that the evidence base for many treatments develops over time.

Hims & Hers acquired a U.S.-based peptide facility in 2025. Wall Street analysts estimate telehealth peptide prescribing could reach $2.2 billion annually if restrictions are eased. Consumer advocates have urged the FDA to require full clinical approval rather than a regulatory workaround.

The FDA is not required to follow the committee's recommendations.